ZBP1 and neoplasm: The sonosensitizer Mn-substituted HfO2 with a 20% Mn ratio (HMO) induces PANoptosis via the oxidative stress–ZBP1 axis, enhancing tumor sensitivity to PD-1 inhibitors (64).